I’m curious to hear the board’s thoughts on the recent actions coming from both the FDA and the White House regarding psychedelic medicines:
https://www.fda.gov/drugs/resources-drugs/psychedelic-drugs
https://www.whitehouse.gov/releases...h-treatments-delivering-new-hope-to-veterans/
The FDA is now publicly stating that it supports the development of psychedelic drugs for serious mental health conditions. It has finalized clinical-development guidance, issued priority-review vouchers, announced a September hearing on the future therapeutic use of psychedelics and entered into a collaboration with the Department of Veterans Affairs. The White House executive order also directs federal agencies to accelerate research and improve access while maintaining FDA standards for safety and efficacy.
At the same time, we are approaching some potentially major regulatory milestones.
Compass Pathways (CMPS) has reported positive results from both of its pivotal Phase 3 trials of COMP360 psilocybin for treatment-resistant depression. Its rolling NDA submission is already underway, with final submission expected during the fourth quarter of 2026 and a possible commercial launch during the first half of 2027, assuming FDA approval and DEA rescheduling.
Definium Therapeutics (DFTX) has also moved deep into Phase 3 with DT120 ODT, its pharmaceutical formulation of lysergide/LSD. It has already reported positive Phase 3 results from Emerge in major depressive disorder, while its two pivotal generalized anxiety disorder trials are fully enrolled. DFTX is not as close to an NDA as CMPS, but several additional Phase 3 results could substantially strengthen its eventual regulatory package.
Then there is Eli Lilly’s agreement to acquire AtaiBeckley (ATAI) for up to $3.8 billion. To me, that may be one of the strongest validations yet that large pharmaceutical companies now view psychedelic-derived medicines as legitimate late-stage neuroscience assets rather than speculative science projects.
There is obviously still clinical, regulatory and execution risk, but it seems difficult to argue that the environment surrounding psychedelic medicines has not changed significantly. Interested to hear whether others see this as a genuine regulatory and industry turning point or whether expectations are getting ahead of reality.
https://www.fda.gov/drugs/resources-drugs/psychedelic-drugs
https://www.whitehouse.gov/releases...h-treatments-delivering-new-hope-to-veterans/
The FDA is now publicly stating that it supports the development of psychedelic drugs for serious mental health conditions. It has finalized clinical-development guidance, issued priority-review vouchers, announced a September hearing on the future therapeutic use of psychedelics and entered into a collaboration with the Department of Veterans Affairs. The White House executive order also directs federal agencies to accelerate research and improve access while maintaining FDA standards for safety and efficacy.
At the same time, we are approaching some potentially major regulatory milestones.
Compass Pathways (CMPS) has reported positive results from both of its pivotal Phase 3 trials of COMP360 psilocybin for treatment-resistant depression. Its rolling NDA submission is already underway, with final submission expected during the fourth quarter of 2026 and a possible commercial launch during the first half of 2027, assuming FDA approval and DEA rescheduling.
Definium Therapeutics (DFTX) has also moved deep into Phase 3 with DT120 ODT, its pharmaceutical formulation of lysergide/LSD. It has already reported positive Phase 3 results from Emerge in major depressive disorder, while its two pivotal generalized anxiety disorder trials are fully enrolled. DFTX is not as close to an NDA as CMPS, but several additional Phase 3 results could substantially strengthen its eventual regulatory package.
Then there is Eli Lilly’s agreement to acquire AtaiBeckley (ATAI) for up to $3.8 billion. To me, that may be one of the strongest validations yet that large pharmaceutical companies now view psychedelic-derived medicines as legitimate late-stage neuroscience assets rather than speculative science projects.
There is obviously still clinical, regulatory and execution risk, but it seems difficult to argue that the environment surrounding psychedelic medicines has not changed significantly. Interested to hear whether others see this as a genuine regulatory and industry turning point or whether expectations are getting ahead of reality.
